Indaptus Therapeutics, Inc. (INDP) stock forecast & analysis
1 analysis. Latest: .
New accounts start with 200 free tokens.
Market Scanner’s AI analysis of Indaptus Therapeutics, Inc. (INDP), updated August 2026: Indaptus Therapeutics' recent price action showed a short-term gain following a longer-term decline, with technical indicators presenting mixed signals.
Summary
Indaptus Therapeutics' recent price action showed a short-term gain following a longer-term decline, with technical indicators presenting mixed signals.
Recent analyses for Indaptus Therapeutics (INDP) covered its price performance over various periods, noting a recent upward trend after a significant monthly decline. Technical indicators such as SMAs, EMA, RSI, MFI, and MACD were examined, alongside fundamental data including market capitalization, EPS, ROE, and historical net losses. News analysis indicated a financial results reporting event but lacked specific details on performance or developments.
INDP technical picture
Indaptus Therapeutics' price action showed a recent 7-day gain following a 30-day decline, with the current price trading below its 50-day and 200-day simple moving averages. Momentum indicators presented mixed signals, with short-term exponential moving average showing upward movement while RSI sat below midpoint and MFI indicated overbought territory.
Fundamentals
The company has consistently reported net losses and negative operating income across annual and quarterly periods. Its market capitalization was reported at $183.9 million, with negative EPS and a negative Return on Equity TTM.
Factors discussed — upside
- 7-day price change of +30.2%
- 91-day price change of +30.2%
- 10-day EMA below current price
- Money Flow Index (MFI) in overbought territory (89.12)
Factors discussed — risks
- 30-day price change of -45.2%
- Current price below 50-day SMA (2.38)
- Current price below 200-day SMA (2.27)
- RSI (14) below midpoint (44.12)
- Consistent net losses reported across annual and quarterly periods
- price performance
- technical indicators
- financial fundamentals
- news events
Summary updated .
Analyses
Recent INDP.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Indaptus Therapeutics, Inc.?
- The bull case for Indaptus Therapeutics (INDP) centers on recent positive price momentum, with a 7-day and 91-day gain suggesting upward trends. Technical indicators, including a 10-day EMA below the current price and an MFI in overbought territory, were noted as potential short-term positive signals.
- What are the risks for Indaptus Therapeutics, Inc.?
- Risks for Indaptus Therapeutics (INDP) include a significant 30-day price decline and the current stock price trading below its 50-day and 200-day SMAs. The RSI is below the midpoint, indicating a lack of strong buying pressure, and the company has consistently reported net losses.
- Is Indaptus Therapeutics, Inc. bullish or bearish?
- Recent AI analyses of Indaptus Therapeutics, Inc. examined factors on both sides. Discussed upside: The bull case for Indaptus Therapeutics (INDP) centers on recent positive price momentum, with a 7-day and 91-day gain suggesting upward trends. Technical indicators, including a 10-day EMA below the current price and an MFI in overbought territory, were noted as potential short-term positive signals. Discussed risks: Risks for Indaptus Therapeutics (INDP) include a significant 30-day price decline and the current stock price trading below its 50-day and 200-day SMAs. The RSI is below the midpoint, indicating a lack of strong buying pressure, and the company has consistently reported net losses. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Indaptus Therapeutics, Inc.?
- Recent analyses for Indaptus Therapeutics (INDP) covered its price performance over various periods, noting a recent upward trend after a significant monthly decline. Technical indicators such as SMAs, EMA, RSI, MFI, and MACD were examined, alongside fundamental data including market capitalization, EPS, ROE, and historical net losses. News analysis indicated a financial results reporting event but lacked specific details on performance or developments.
- Bundles used
- gemini-low-v2
Run a fresh INDP.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every INDP.US report already in the library